Phase I single ascending dose trial of Z 944.

Next Previous
Trial Profile

Phase I single ascending dose trial of Z 944.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2012

At a glance

  • Drugs Z 944 (Primary)
  • Indications Pain
  • Focus Adverse reactions

    • Most Recent Events

    • 19 Jun 2012 The primary endpoint, 'Maximum tolerated dose', has been met, according to a Zalicus media release.
    • 19 Jun 2012 Status changed from recruiting to completed.
    • 03 May 2012 Location changed from USA to United Kingdom, according to a Zalicus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top